American Heart Association In Brief: Perclose
This article was originally published in The Gray Sheet
Executive Summary
Perclose: Four hundred-patient study presented at AHA finds that the firm's Techstar percutaneous vascular surgical closure device is associated with a "statistically significant reduction of major and minor complications" versus manual compression, Perclose says. A study of 400 diagnostic catheterization patients found that major complications occurred in 0.5% of Techstar patients and 2.5% of manual compression patients. Minor complication rates were 3.9% and 10.1% for Techstar and non-Techstar patients, respectively. The study also found a reduced time to ambulation (1 hour vs. 20.3 hours) in the Techstar group. A second, 200-patient study evaluating use of Techstar in angioplasty and stent procedures also finds faster ambulation time (4.1 hours vs. 14.7 hours) in the Techstar group...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.